This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Olanzapine May Cause Delirium in Geriatric Patients

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Olanzapine, a second-generation antipsychotic, is indicated by the U.S. Food and Drug Administration (FDA) for schizophrenia and bipolar I acute mania but has limited evidence for use in elderly patients with these conditions.1 Olanzapine was FDA-approved in December 2003 for maintenance monotherapy for bipolar disorder. Olanzapine at doses up to 20 mg is recommended to treat schizophrenia and acute mania.2 The package insert, however, recommends a lower dosage in geriatric patients, based upon studies of elderly with schizophrenia or dementia with psychotic symptoms, not those with acute mania.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Psychopharmacology